Trials / NCT05158296
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Terminated Phase 2 / Phase 3 RNA / antisense
Why it stopped: Business decision
- Sponsor
- Laboratoires Thea
- Treatment
- Ultevursen; Sham-procedure
- Gene
- USH2A
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Ages
- 12 Years to no upper limit
- Enrollment
- 7 participants
- Started
- 2021-12-08
- Main results expected
- 2022-10-12
- Results posted
- Yes
- Record last updated
- 2024-07-12
What the study is testing
The purpose of this study is to evaluate the efficacy safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
Where it runs
Germany (1)
- Universitaetsklinikum Tuebingen Department für Augenheilkunde, Tübingen
Netherlands (2)
- RadboudUMC, Nijmegen
- Het Oogziekenhuis Rotterdam, Rotterdam
United Kingdom (2)
- Oxford Eye Hospital, Headington, Oxford
- Moorfields Eye Hospital, London
United States (10)
- Shiley Eye Institute - UC San Diego, San Diego, California
- University of California, San Francisco, San Francisco, California
- University of Miami, Bascom Palmer Eye Institute, Miami, Florida
- Emory Eye Center, Atlanta, Georgia
- Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland
- Center for Clinical Research Operations, Massachusetts Eye and Ear, Boston, Massachusetts
- University of Michigan, Kellogg Eye Center, Ann Arbor, Michigan
- Columbia University, New York, New York
- Retina Foundation of the Southwest, Dallas, Texas
- University of Wisconsin - Madison, Madison, Wisconsin